Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
about
Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.Afatinib in advanced NSCLC: a profile of its use.The emerging treatment landscape of advanced non-small cell lung cancer.Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
P2860
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment choice in epidermal ...... nce and clinical implications.
@en
Treatment choice in epidermal ...... nce and clinical implications.
@nl
type
label
Treatment choice in epidermal ...... nce and clinical implications.
@en
Treatment choice in epidermal ...... nce and clinical implications.
@nl
prefLabel
Treatment choice in epidermal ...... nce and clinical implications.
@en
Treatment choice in epidermal ...... nce and clinical implications.
@nl
P2860
P356
P1476
Treatment choice in epidermal ...... ence and clinical implications
@en
P2093
Oscar Juan
Sanjay Popat
P2860
P304
P356
10.1177/1758834016687262
P577
2017-01-30T00:00:00Z